

#14  
GND

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

**PATENT**  
Attorney Docket No.: 018623-006240US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On January 8, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Joy M. Marshall

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SETTE et al.

Application No.: 09/709,774

Filed: November 8, 2000

For: ALTERATION OF IMMUNE  
RESPONSE USING PAN DR-BINDING  
PEPTIDES

Examiner: DeCloux, Amy M.

Art Unit: 1644

**RESPONSE TO RESTRICTION**

**RECEIVED**

JAN 15 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit this response with reference to the Office Communications mailed December 13, 2002 and July 2, 2002.

**REMARKS**

The Examiner noted that the species elected in Paper 12 was not acceptable because the species was not encompassed by the claim.

Applicants previously elected with traverse the claims of Group I (claims 18-26), drawn to a polynucleotide encoding a fusion protein. Applicants hereby elect the following species: a fusion protein comprising the pan Dr binding sequence AKFVAAWTLKAAA (i.e., where R1=AK, R2=F, R3=VAA, R4=WTLK and R5=AAA) and an immunogenic peptide. Claims 18-26 read on this species.